Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be reviewed, with emphasis on patient selection and neuropathy management.

The webinar will be delivered by Dr. Malcolm Moore, Program Head, Medical Oncology and Hematology, Director, McCain Centre for Pancreatic Cancer; Professor, Department of Medicine and Pharmacology, University of Toronto.

Learning Objectives

1. To review the design and key results from the MPACT (Gemcitabine /- nab-paclitaxel) in advanced pancreatic cancer.
2. To discuss potential treatment toxicity (especially neuropathy) and any practical issues
3. To outline future opportunities in the therapy of pancreatic cancer.